跳至主要内容
临床试验/NCT01453686
NCT01453686已完成3 期

A Randomized Controlled Trial of Clobetasol Propionate 0.05% Cream Versus Hydrocortisone 1% Cream in Children With Alopecia Areata

The Hospital for Sick Children1 个研究点 分布在 1 个国家目标入组 41 人开始时间: 2002年8月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
41
试验地点
1
主要终点
Change in scalp surface area affected over time

研究概览

简要总结

The use of topical steroids in the treatment of alopecia areata in children is common practice. However, no particular potency of steroid is accepted as the standard treatment due to the paucity of high quality evidence in the dermatology literature to substantiate their use. Two randomized controlled trials exist assessing topical steroid efficacy in this disorder, both have methodological limitations. The question remains as to which topical steroid is safe and efficacious for use. We performed a double blinded controlled trial to assess the usefulness of a class 1 topical steroid (clobestasol proprionate 0.05%) compared with a class 7 topical steroid (hydrocortisone 1%) in children with alopecia areata.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
2 Years 至 16 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Age 2 to 16 years
  • New patients presenting to The Hospital for Sick Children
  • Clinical confirmation of alopecia areata
  • Hair loss between 10 -75%

排除标准

  • Skin or medical problems requiring use of oral steroids
  • Immunosuppressants or PUVA for 4 weeks prior to the study
  • Use of inhaled and or intranasal steroids for 14 days prior to trial
  • Topical medicaments for 7 days prior to the trial

研究组 & 干预措施

Hydrocortisone 1%

Experimental

干预措施: Hydrocortisone 1% (Drug)

Clobetasol Propionate 0.05%

Experimental

干预措施: Clobetasol Propionate 0.05% (Drug)

结局指标

主要结局

Change in scalp surface area affected over time

时间窗: 24 weeks

The change in scalp surface area affected will be compared between the two intervention groups from baseline to 6 weeks, 12 weeks, and 24 weeks.

次要结局

  • Change in scalp surface area affected from baseline to end of study(24 weeks)
  • Over 50% reduction in scalp surface area affected(24 weeks)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Patricia Parkin

Staff Paediatrician

The Hospital for Sick Children

研究点 (1)

Loading locations...

相似试验

A Trial of Clobetasol Propionate Versus... | 临床试验